#74 Lung Transplantion in the ICU
In this episode of Critical Care Time, we tackle one of the most complex and high-stakes corners of critical care: the lung transplant patient in the ICU. From evaluating candidates at the edge of respiratory failure to managing the crashing post-transplant patient, we break down the practical bedside decisions that matter most — including bridge strategies, hemodynamics, immunosuppression, infection, rejection, and the complications that can rapidly spiral if you miss them. Whether you work in a transplant center or occasionally inherit these patients in a general ICU, this episode is built to give you a sharper framework, clearer priorities, and more confidence when the stakes are highest. As is often the case, a heavy lift like this needs some back up and we are grateful to have Dr. Lara Jones, a transplant pulmonologist and her colleague, Dr. Jason Gauthier, a thoracic surgeon on to help us with this one!
Pre-Transplant ICU Management and Candidacy
When a listed patient deteriorates and requires ICU-level care, Candidacy in the ICU is never static—it’s a continuous reassessment of risk, reversibility, and physiologic reserve and a decision we make as a committee. Together the transplant and ICU team must answer three core questions:
whether the deterioration reflects progression of the underlying lung disease
whether any new problem is reversible
whether there is a clear and achievable path to recovery.
If the ICU admission reflects progression of the patient’s lung disease, the decision is relatively straightforward: the patient remains listed, and the team focuses on optimizing support while awaiting an organ offer. However, if the deterioration is due to a new process, such as infection, medication effects, bleeding, or new organ dysfunction, the question becomes whether that process is reversible and whether recovery will restore transplant candidacy.
A central concern is the “frailty cascade.” Critically ill transplant candidates often have limited physiologic reserve, and even short periods of immobility can lead to rapid deconditioning, sarcopenia, and loss of transplant eligibility.
Mechanical Ventilation: Bridge or Liability
While mechanical ventilation may be essential, providing temporary stabilization, it frequently initiates a cascade of complications that can jeopardize transplant eligibility.
The primary concern is not simply ventilator-induced lung injury but the systemic consequences of sedation and immobility: Sedation drives delirium, delirium drives immobility, and immobility drives deconditioning and frailty. Once that cascade starts, patients can miss their transplant window.
There are exceptions, particularly when mechanical ventilation is delivered via tracheostomy with the explicit goal of maintaining wakefulness and mobility. In some centers, patients can remain interactive and even ambulatory while mechanically ventilated. However, once ventilation prevents participation in rehabilitation, it ceases to function as a bridge and instead becomes a liability for transplant.
ECMO as a Bridge to Transplant
“The goal is to keep them alive. If there’s time to think about options, then you should, otherwise cannulate.”
Extracorporeal membrane oxygenation (ECMO) has emerged as a critical tool for bridging patients to lung transplantation. Its use, however, requires careful patient selection, timing, and institutional expertise.
Most lung transplant candidates require veno-venous ECMO, which provides respiratory support while preserving cardiac function. A central goal is not just survival but preservation of end-organ function and the ability to participate in rehabilitation. Awake ECMO strategies, which allow patients to remain extubated and mobile, are increasingly favored but require significant resources and expertise.
The timing of ECMO initiation is nuanced. Teams often delay cannulation as long as the patient can maintain adequate oxygenation, ventilation, and mobility. However, once these are compromised, like with mechanical ventilation, ECMO may initiate a spiral of irreversible deconditioning.
Ethical Considerations in ECMO Bridging
ECMO as a bridge to transplant is both resource-intensive and ethically complex.
ECMO is only justified if there is a realistic path to transplant and meaningful recovery. This requires continuous reassessment of organ function, neurologic status, and overall trajectory. When patients develop progressive multi-organ failure or irreversible injury, ECMO transitions from a bridge to non-beneficial life support.
Three important considerations:
defining futility
maintaining transparency
establishing an exit strategy
Primary Graft Dysfunction
Primary graft dysfunction (PGD) is one of the most important early complications after lung transplantation. It is defined by hypoxemia and radiographic infiltrates within the first 72 hours in the absence of another clear cause. Or more simply “the ARDS of the lung transplant patient.”
The pathophysiology involves ischemia-reperfusion injury leading to non-cardiogenic pulmonary edema. Diagnosis is challenging because PGD can be difficult to distinguish from volume overload or infection in the immediate postoperative period.
Management is primarily supportive, with strict lung-protective ventilation, careful fluid balance, and a low threshold for ECMO.
Early Surgical Complications
Early postoperative complications include bleeding, hemothorax, and bronchial anastomotic issues. Hemothorax is relatively common, and early drainage is essential to prevent retained collections requiring surgical intervention.
Bronchial anastomotic dehiscence is less common but potentially serious. It typically presents with respiratory symptoms such as cough or stridor, or with declining pulmonary function. In the immediate postoperative period, a new large air leak should raise concern and prompt evaluation.
Rejection vs Infection
When transplant patients develop new infiltrates or physiologic decline, distinguishing rejection from infection is essential but often difficult. Early after transplant, infection is more common, particularly given the high level of immunosuppression.
Evaluation typically includes bronchoscopy with biopsy and microbiologic sampling, along with donor-specific antibody testing. Treatment depends on the underlying process, with steroids used for cellular rejection and plasmapheresis and rituximab for antibody-mediated rejection.
Empiric therapy may be necessary when diagnostic procedures are delayed, but the goal is to base treatment on objective data whenever possible.
Common Opportunistic Infections
Lung transplant recipients are uniquely vulnerable to infection because the transplanted organ is directly exposed to the environment and the host is intentionally immunosuppressed.
Viral infections and fungal infections are more common earlier. Bacterial infections become more common later. (see timeline below)
Common pitfalls include underestimating infections in patients on prophylaxis, misinterpreting colonization as infection, and missing atypical presentations of pathogens such as CMV or invasive fungi. Even in the absence of classic signs of sepsis, unexplained hypoxemia or radiographic changes should prompt a broad infectious evaluation.
This interactive graphic is open source. Check out the source code here.
Chronic Lung Allograft Dysfunction
Chronic lung allograft dysfunction (CLAD) is the major determinant of long-term outcomes after lung transplantation. Although often considered an outpatient issue, its roots are frequently established during the ICU course.
Key risk factors include primary graft dysfunction, aspiration and foregut dysfunction, acute kidney injury, viral infections, and sensitizing events such as blood transfusions. These findings underscore the importance of meticulous ICU care not only for short-term survival but for long-term graft function.
Goals of Care
When lung transplant patients deteriorate months or years after transplant and retransplantation is not feasible, clinicians face some of the most challenging conversations in critical care.
Framing prognosis involves focusing on trajectory, physiologic reserve, and whether recovery aligns with the patient’s values. Early involvement of palliative care is invaluable in these situations.
Key Takeaways
Lung transplant candidacy in the ICU is dynamic and requires continuous reassessment of physiologic reserve and reversibility. Mechanical ventilation is often harmful unless it can be delivered in a way that preserves mobility and participation in rehabilitation. ECMO can serve as a powerful bridge to transplant, but its use must be guided by clear goals, defined limits, and ethical transparency.
Early postoperative complications, particularly primary graft dysfunction, have profound implications for long-term outcomes. Distinguishing infection from rejection requires careful evaluation and often invasive diagnostics. Finally, ICU care has lasting consequences: decisions made in the first days and weeks after transplant shape the trajectory of graft survival and patient outcomes for years to come.
This Episode was proudly sponsored by:
